vs

Side-by-side financial comparison of GSI TECHNOLOGY INC (GSIT) and Lineage Cell Therapeutics, Inc. (LCTX). Click either name above to swap in a different company.

Lineage Cell Therapeutics, Inc. is the larger business by last-quarter revenue ($6.6M vs $6.1M, roughly 1.1× GSI TECHNOLOGY INC). Lineage Cell Therapeutics, Inc. runs the higher net margin — 12.9% vs -49.7%, a 62.6% gap on every dollar of revenue. On growth, Lineage Cell Therapeutics, Inc. posted the faster year-over-year revenue change (130.4% vs 12.2%). Lineage Cell Therapeutics, Inc. produced more free cash flow last quarter ($-5.3M vs $-8.2M). Over the past eight quarters, Lineage Cell Therapeutics, Inc.'s revenue compounded faster (113.9% CAGR vs 8.6%).

Triad GSI is an American voting machine vendor based in Xenia, Ohio. Their main products are election-related computer hardware and software for counting ballots, as well as voter registration.

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to eithe...

GSIT vs LCTX — Head-to-Head

Bigger by revenue
LCTX
LCTX
1.1× larger
LCTX
$6.6M
$6.1M
GSIT
Growing faster (revenue YoY)
LCTX
LCTX
+118.2% gap
LCTX
130.4%
12.2%
GSIT
Higher net margin
LCTX
LCTX
62.6% more per $
LCTX
12.9%
-49.7%
GSIT
More free cash flow
LCTX
LCTX
$2.9M more FCF
LCTX
$-5.3M
$-8.2M
GSIT
Faster 2-yr revenue CAGR
LCTX
LCTX
Annualised
LCTX
113.9%
8.6%
GSIT

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
GSIT
GSIT
LCTX
LCTX
Revenue
$6.1M
$6.6M
Net Profit
$-3.0M
$851.0K
Gross Margin
52.7%
Operating Margin
-113.7%
-99.1%
Net Margin
-49.7%
12.9%
Revenue YoY
12.2%
130.4%
Net Profit YoY
25.0%
126.0%
EPS (diluted)
$-0.09
$0.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GSIT
GSIT
LCTX
LCTX
Q4 25
$6.1M
$6.6M
Q3 25
$6.4M
$3.7M
Q2 25
$6.3M
$2.8M
Q1 25
$5.9M
$1.5M
Q4 24
$5.4M
$2.9M
Q3 24
$4.5M
$3.8M
Q2 24
$4.7M
$1.4M
Q1 24
$5.2M
$1.4M
Net Profit
GSIT
GSIT
LCTX
LCTX
Q4 25
$-3.0M
$851.0K
Q3 25
$-3.2M
$-29.8M
Q2 25
$-2.2M
$-30.5M
Q1 25
$-2.2M
$-4.1M
Q4 24
$-4.0M
$-3.3M
Q3 24
$-5.5M
$-3.0M
Q2 24
$1.1M
$-5.8M
Q1 24
$-4.3M
$-6.5M
Gross Margin
GSIT
GSIT
LCTX
LCTX
Q4 25
52.7%
Q3 25
54.8%
Q2 25
58.1%
Q1 25
56.1%
97.6%
Q4 24
54.0%
94.6%
Q3 24
38.6%
99.0%
Q2 24
46.3%
96.9%
Q1 24
51.6%
93.2%
Operating Margin
GSIT
GSIT
LCTX
LCTX
Q4 25
-113.7%
-99.1%
Q3 25
-49.5%
-102.9%
Q2 25
-34.6%
-715.4%
Q1 25
-38.7%
-433.1%
Q4 24
-74.9%
-178.2%
Q3 24
-122.7%
-101.6%
Q2 24
23.1%
-416.7%
Q1 24
-87.6%
-461.3%
Net Margin
GSIT
GSIT
LCTX
LCTX
Q4 25
-49.7%
12.9%
Q3 25
-49.4%
-809.0%
Q2 25
-35.3%
-1101.8%
Q1 25
-37.9%
-275.6%
Q4 24
-74.4%
-114.1%
Q3 24
-120.0%
-80.3%
Q2 24
23.1%
-409.1%
Q1 24
-83.9%
-453.0%
EPS (diluted)
GSIT
GSIT
LCTX
LCTX
Q4 25
$-0.09
$0.00
Q3 25
$-0.11
$-0.13
Q2 25
$-0.08
$-0.13
Q1 25
$-0.09
$-0.02
Q4 24
$-0.16
$0.00
Q3 24
$-0.21
$-0.02
Q2 24
$0.04
$-0.03
Q1 24
$-0.17
$-0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GSIT
GSIT
LCTX
LCTX
Cash + ST InvestmentsLiquidity on hand
$70.7M
$55.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$83.6M
$44.5M
Total Assets
$98.5M
$112.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GSIT
GSIT
LCTX
LCTX
Q4 25
$70.7M
$55.8M
Q3 25
$25.3M
$40.5M
Q2 25
$22.7M
$42.3M
Q1 25
$13.4M
$47.9M
Q4 24
$15.1M
$47.8M
Q3 24
$18.4M
$32.7M
Q2 24
$21.8M
$38.5M
Q1 24
$14.4M
$43.6M
Stockholders' Equity
GSIT
GSIT
LCTX
LCTX
Q4 25
$83.6M
$44.5M
Q3 25
$38.6M
$22.0M
Q2 25
$37.4M
$48.4M
Q1 25
$28.2M
$79.0M
Q4 24
$29.9M
$78.4M
Q3 24
$33.3M
$66.2M
Q2 24
$38.0M
$68.3M
Q1 24
$36.0M
$72.4M
Total Assets
GSIT
GSIT
LCTX
LCTX
Q4 25
$98.5M
$112.6M
Q3 25
$52.0M
$89.6M
Q2 25
$50.5M
$90.8M
Q1 25
$43.3M
$111.8M
Q4 24
$44.1M
$113.2M
Q3 24
$47.4M
$96.6M
Q2 24
$52.3M
$102.8M
Q1 24
$42.5M
$108.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GSIT
GSIT
LCTX
LCTX
Operating Cash FlowLast quarter
$-7.9M
$-4.9M
Free Cash FlowOCF − Capex
$-8.2M
$-5.3M
FCF MarginFCF / Revenue
-134.4%
-79.9%
Capex IntensityCapex / Revenue
4.9%
6.0%
Cash ConversionOCF / Net Profit
-5.73×
TTM Free Cash FlowTrailing 4 quarters
$-12.5M
$-19.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GSIT
GSIT
LCTX
LCTX
Q4 25
$-7.9M
$-4.9M
Q3 25
$-887.0K
$-3.6M
Q2 25
$-1.7M
$-5.5M
Q1 25
$-1.7M
$-4.9M
Q4 24
$-3.6M
$-6.3M
Q3 24
$-3.5M
$-5.8M
Q2 24
$-4.3M
$-5.2M
Q1 24
$-7.1M
$-5.8M
Free Cash Flow
GSIT
GSIT
LCTX
LCTX
Q4 25
$-8.2M
$-5.3M
Q3 25
$-906.0K
$-3.6M
Q2 25
$-1.7M
$-5.6M
Q1 25
$-1.7M
$-5.0M
Q4 24
$-3.6M
$-6.7M
Q3 24
$-3.5M
$-5.9M
Q2 24
$-4.3M
$-5.2M
Q1 24
$-7.2M
$-5.8M
FCF Margin
GSIT
GSIT
LCTX
LCTX
Q4 25
-134.4%
-79.9%
Q3 25
-14.1%
-98.6%
Q2 25
-27.6%
-200.8%
Q1 25
-28.3%
-331.8%
Q4 24
-66.1%
-234.0%
Q3 24
-76.6%
-156.1%
Q2 24
-92.0%
-371.2%
Q1 24
-139.0%
-403.1%
Capex Intensity
GSIT
GSIT
LCTX
LCTX
Q4 25
4.9%
6.0%
Q3 25
0.3%
0.3%
Q2 25
0.3%
0.5%
Q1 25
0.1%
6.5%
Q4 24
0.1%
12.7%
Q3 24
0.1%
3.0%
Q2 24
0.7%
3.6%
Q1 24
0.2%
2.6%
Cash Conversion
GSIT
GSIT
LCTX
LCTX
Q4 25
-5.73×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
-3.96×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GSIT
GSIT

Distribution$5.6M92%
Other$459.0K8%

LCTX
LCTX

Collaboration Revenues$6.3M95%
Other$345.0K5%

Related Comparisons